Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Abdelmajid H. Alnatsheh"'
Autor:
Mansoor A. Khan, Mohammed A. Aseeri, Majed A. Alshamrani, Abdelmajid H. Alnatsheh, Hani S. Alhamdan
Publikováno v:
Global Journal on Quality and Safety in Healthcare, Pp 1-8 (2020)
Biologics are significant drivers of globally escalating healthcare costs. Biosimilars have potential to offer cost savings with comparable efficacy and safety to innovator products and increase the access of treatment to more patients. This study ai
Externí odkaz:
https://doaj.org/article/1ad384fd5e6142fb972b7b6d4937d019
Publikováno v:
Journal of Oncology Pharmacy Practice. 28:771-776
Background The discovery of immune checkpoint inhibitors caused a paradigm shift in cancer treatment and led to a major improvement in clinical outcomes. However, they may induce inflammatory side effects that are known as immune-related adverse effe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b333e29cb185a8f277eae0503d0137e
https://doi.org/10.1177/10781552211017634
https://doi.org/10.1177/10781552211017634
Publikováno v:
Global Journal on Quality and Safety in Healthcare. 3:22-29
Biologics are significant drivers of globally escalating healthcare costs. Biosimilars have potential to offer cost savings with comparable efficacy and safety to innovator products and increase the access of treatment to more patients. This study ai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f28aa58a80976ff08f2bf860ed53d2cc
https://doi.org/10.4103/jqsh.jqsh_15_19
https://doi.org/10.4103/jqsh.jqsh_15_19
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 25(4)
Objective The purpose of this study is to compare the incidence of venous thromboembolism between obese and non-obese hospitalized patients who received United States Food and Drug Administration-approved prophylactic enoxaparin doses and to describe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76023d2f411c72c3bd368c3df471d2cd
https://pubmed.ncbi.nlm.nih.gov/29486637
https://pubmed.ncbi.nlm.nih.gov/29486637
Autor:
Afnan Mohammed Noor, Mansoor Ahmed Khan, Muteb M Al-Thomali, Abdelmajid H Alnatsheh, Ahmed A Absi, Fahad M Hakami, Majed A Alshamrani
Publikováno v:
Journal of Applied Hematology, Vol 13, Iss 3, Pp 126-131 (2022)
CONTEXT: Tyrosine kinase inhibitors (TKIs) are the standard of care therapy for chronic myeloid leukemia (CML). The current disadvantages of lifelong treatment include adverse effects and financial burden. AIMS: This study aimed to evaluate the outco
Externí odkaz:
https://doaj.org/article/38ae3701b2464015a50e38aea758d797